Luye Pharma
3
203M
3
0.10
1
- Areas of investment
Summary
Luye Pharma is the famous Corporate Investor, which was founded in 1994. The leading representative office of defined Corporate Investor is situated in the Shanghai. The fund was located in Asia if to be more exact in China.
Deals in the range of more than 100 millions dollars are the general things for fund. The high activity for fund was in 2017. The fund is constantly included in less than 2 deals per year.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the Luye Pharma, startups are often financed by Tempus, Shenzhen Capital Group, Patrick G. Ryan. The meaningful sponsors for the fund in investment in the same round are Total Access Fund, The Yard Ventures, Purple Arch Ventures.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Consumer, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Exicure, LeEco. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Rounds per year
- 0.10
- Investments by industry
- Biotechnology (2)
- Life Science (1)
- Therapeutics (1)
- Genetics (1)
- Video (1) Show 4 more
- Investments by region
-
- China (1)
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 231M
- Group Appearance index
- 1.00
- Strategy success index
- 0.33
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Lituo Biotechnology | 07 Jul 2022 | Biotechnology, Artificial Intelligence, Agriculture | Seed |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.